ID | 62038 |
フルテキストURL | |
著者 |
Matsumoto, Jun
Department of Personalized Medicine and Preventive Healthcare Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
ORCID
Kaken ID
researchmap
Kotera, Yumi
Department of Personalized Medicine and Preventive Healthcare Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Watari, Shogo
Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Takeuchi, Koichi
Department of Personalized Medicine and Preventive Healthcare Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Kaken ID
publons
researchmap
Ueki, Hideo
Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Koyama, Toshihiro
Department of Pharmaceuticals Biomedicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
ORCID
Kaken ID
publons
researchmap
Wada, Koichiro
Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
ORCID
researchmap
Fujiyoshi, Masachika
Department of Personalized Medicine and Preventive Healthcare Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Nasu, Yasutomo
Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Ariyoshi, Noritaka
Department of Personalized Medicine and Preventive Healthcare Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Kaken ID
researchmap
|
抄録 | Background/Aim: This study aimed to elucidate the detailed characteristics of CYP3A5 expression and the association between CYP3A5 expression and clinical outcomes in patients with renal cell carcinoma (RCC). Patients and Methods: This study retrospectively enrolled 124 Japanese patients with RCC treated at the Okayama University Hospital. The commonest CYP3A5 gene polymorphism, CYP3A5*3, and expression levels of CYP3A5 mRNA and protein in each tissue were examined. Results: Expression of CYP3A5 mRNA and protein in RCC tissues was significantly down-regulated compared to that in adjacent normal tissues. High level of CYP3A5 mRNA expression significantly extended cancer-specific survival (p=0.004) and overall survival (p=0.002). The CYP3A5 mRNA expression level was identified as a significant independent prognostic factor for both cancer-specific survival and overall survival. Conclusion: CYP3A5 could serve as a potential marker for prognostication and treatment planning for patients with RCC.
|
キーワード | human
cytochrome P450 CYP3A
renal cell carcinoma treatment outcome
|
発行日 | 2021-5
|
出版物タイトル |
Anticancer Research
|
巻 | 41巻
|
号 | 5号
|
出版者 | International Institute of Anticancer Research
|
開始ページ | 2511
|
終了ページ | 2521
|
ISSN | 0250-7005
|
NCID | AA10625860
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
著作権者 | Copyright © 2021 by The International Institute of Anticancer Research
|
論文のバージョン | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.21873/anticanres.15029
|
助成機関名 |
Japan Society for the Promotion of Science
KAWASAKI Foundation for Medical Science and Medical Welfare
|
助成番号 | 20K16043
|
オープンアクセス(出版社) |
非OA
|